The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant

https://doi.org/10.1016/j.lrr.2018.06.003Get rights and content
Under a Creative Commons license
open access

Abstract

Activating mutations in FLT3 in acute myeloid leukemia (AML) portend a poor prognosis, and targeting FLT3 with a tyrosine kinase inhibitor has been an area of intense research recently. Most FLT3 mutated AML patients undergo hematopoietic stem cell transplantation (HSCT) as standard of care but a significant proportion of patients relapse. Although the use of FLT3 inhibitors in the pre-HSCT perspective is more clearly defined, its use in the post-HSCT scenario, when most relapses occur, remains unclear. In this review, we comprehensively present the data on the recent and ongoing studies evaluating the role of various FLT3 inhibitors in AML with a particular focus in the post-HSCT setting.

Keywords

Acute myeloid leukemia
FLT3
Hematopoietic stem cell transplant
Tyrosine kinase inhibitors
Multikinase inhibitors
Drug resistance

Cited by (0)

1

Both authors contribute equally to this work.